Related to Genotyping HCV Patients for HLA-C and IL28B Improves Ability to Predict Treatment Response

• The Underappreciated Cost-Saving Potential of Personalized Medicine in Health Reform Debate
  The current draft includes comparative effectiveness research but does not provide nearly as much funding as is needed for CER.
  
• Jumping On Genetic Testing—The War of the SNPs
  Molecular diagnostics still have a long way to go before they can properly deliver on all their promises.
  
• Avastin: Time for a Predictive Test
  Roche’s strategy to expand the use of Avastin into the first-line and adjuvant settings is particularly dependent on identifying those most likely to see a benefit.
  
• Biomarkers Poised for Breakout Moment
  A passel of discussions at BIO highlight the importance of these disease-state indicators.
  
• Getting Personal: Multigene Testing for Individual Cancer Evaluation
  Scientists find comfort in numbers, using molecular patterns as prognostic markers.
  
• Tumor Cells Back in Circulation for Monitoring Cancer
  With one test on the market, researchers are developing tools that leverage CTCs as biomarkers.
  
• Diagnostic Market Stakeholders Take Aim at FDA’s RUO/IUO Draft Guidance
  Among potential changes is that manufacturers will have to anticipate customers’ intended use of their IVD products.
  
• Concurrent Dx/Rx Review Will Require More Collaboration at FDA and More Outreach by Industry
  Agency issued draft guidance on companion diagnostic approval on July 14.
  
• Companies with Cancer Therapeutic Candidates Ramp Up Companion Diagnostic Efforts
  As regulatory framework gets fine-tuned, firms realize the importance of having a biomarker strategy.
  
• Standardization Key to Taking Next-Generation Sequencing to the Next Level
  As NGS technology makes steady progress with faster and cheaper machines, regulation will have to keep up.
  
• This Time Last Year: Diagnostic Deals, mAb Therapeutics, and Obesity Drug Development
  Among big news was Roche’s companion diagnostic alliance with Clovis, a melanoma deal with BMS, and FDA’s Avastin decision.
  
• Companion Diagnostics: 52 Pick-Up
  Check out our three lists of 52 CDx: those approved by the FDA, those under review right now, and those that may be coming soon.
  
• Tales from the Biotech Crypt: Sam Waksal Is Back in Business
  Former ImClone CEO has started a new firm, made three acquisitions including Three Rivers, and begun licensing.